The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on December ....
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.5 pts more than Nifty Microcap 250 and 6.1 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Docon Technologies Private Limited, the promoter and holding company of Thyrocare Technologies, has disclosed a fresh auto-encumbrance (pledge) on 6,46,46,464 bonus shares allotted on December 1, 2025 under a 2:1 bonus issue. After this, total encumbered shares stand at 9,69,69,696, still representing 60.93% of Thyrocare's paid-up equity capital. The pledge is in favour of Catalyst Trusteeship Limited, acting as debenture trustee for secured, unlisted, redeemable, non-convertible debentures worth up to ₹12,000 million issued by API Holdings Limited. The value of the encumbered shares is approximately ₹45,013.33 million based on Thyrocare's closing price of ₹464.20 on December 2, 2025. No new debt has been raised; this is an automatic extension of existing pledge due to the bonus issuance.
This is a procedural disclosure arising from the bonus issue and does not change the promoter's economic stake or the pledged percentage. Existing shareholders should note that over 60% of Thyrocare's shares are pledged to secure API Holdings' debentures, which represents a significant concentration of encumbrance risk on the promoter holding.